142 related articles for article (PubMed ID: 25646943)
1. Efficacy and safety of saxagliptin as add-on therapy in type 2 diabetes.
Neumiller JJ
Clin Diabetes; 2014 Oct; 32(4):170-7. PubMed ID: 25646943
[TBL] [Abstract][Full Text] [Related]
2. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.
Barnett AH; Charbonnel B; Donovan M; Fleming D; Chen R
Curr Med Res Opin; 2012 Apr; 28(4):513-23. PubMed ID: 22313154
[TBL] [Abstract][Full Text] [Related]
3. Clinical overview of saxagliptin for Type 2 diabetes management.
Rosenstock J
Expert Rev Endocrinol Metab; 2010 Nov; 5(6):809-823. PubMed ID: 30780831
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.
Barnett AH; Charbonnel B; Moses RG; Kalra S
Curr Med Res Opin; 2015; 31(10):1919-31. PubMed ID: 26361231
[TBL] [Abstract][Full Text] [Related]
5. Saxagliptin for type 2 diabetes.
Chacra AR
Diabetes Metab Syndr Obes; 2010 Sep; 3():325-35. PubMed ID: 21437102
[TBL] [Abstract][Full Text] [Related]
6. Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies.
Schwartz SL
Ann Med; 2012 Mar; 44(2):157-69. PubMed ID: 22132773
[TBL] [Abstract][Full Text] [Related]
7. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes.
Lam S; Saad M
Cardiol Rev; 2010; 18(4):213-7. PubMed ID: 20539105
[TBL] [Abstract][Full Text] [Related]
8. Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials.
Cook W; Bryzinski B; Slater J; Frederich R; Allen E
Postgrad Med; 2013 May; 125(3):145-54. PubMed ID: 23748515
[TBL] [Abstract][Full Text] [Related]
9. Saxagliptin efficacy and safety in patients with type 2 diabetes receiving concomitant statin therapy.
Bryzinski B; Allen E; Cook W; Hirshberg B
J Diabetes Complications; 2014; 28(6):887-93. PubMed ID: 25168266
[TBL] [Abstract][Full Text] [Related]
10. Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes.
Lajara R
Expert Opin Pharmacother; 2012 Dec; 13(18):2663-71. PubMed ID: 23137412
[TBL] [Abstract][Full Text] [Related]
11. Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot study.
Elkind-Hirsch KE; Paterson MS; Seidemann EL; Gutowski HC
Fertil Steril; 2017 Jan; 107(1):253-260.e1. PubMed ID: 28228317
[TBL] [Abstract][Full Text] [Related]
12. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Deacon CF; Holst JJ
Adv Ther; 2009 May; 26(5):488-99. PubMed ID: 19444391
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.
Fass AD; Gershman JA
Adv Ther; 2013 Apr; 30(4):337-53. PubMed ID: 23605247
[TBL] [Abstract][Full Text] [Related]
14. Effects of Glimepiride versus Saxagliptin on β-Cell Function and Hypoglycemia: A Post Hoc Analysis in Older Patients with Type 2 Diabetes Inadequately Controlled with Metformin.
Perl S; Cook W; Wei C; Ohman P; Hirshberg B
Clin Ther; 2016 Dec; 38(12):2578-2588. PubMed ID: 27823868
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.
Hermann LS; Scherstén B; Bitzén PO; Kjellström T; Lindgärde F; Melander A
Diabetes Care; 1994 Oct; 17(10):1100-9. PubMed ID: 7821128
[TBL] [Abstract][Full Text] [Related]
16. Saxagliptin in type 2 diabetes.
Billiones R
Drugs Today (Barc); 2010 Feb; 46(2):101-8. PubMed ID: 20393638
[TBL] [Abstract][Full Text] [Related]
17. Metformin + saxagliptin for type 2 diabetes.
Scheen AJ
Expert Opin Pharmacother; 2012 Jan; 13(1):139-46. PubMed ID: 22149373
[TBL] [Abstract][Full Text] [Related]
18. Complementing insulin therapy to achieve glycemic control.
Barnett AH
Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
